Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.

JCO precision oncology - 1 Oct 2024

Fatteh Maria, Wehr Jaime, Karaindrou Katerina, Xian Rena R, Gocke Christopher, Lin Ming-Tseh, Petry Dana, Visvanathan Kala, Couzi Rima, Santa Maria Cesar, Stearns Vered, Tao Jessica J, Anagnostou Valsamo, Canzoniero Jenna V

Abstract excerpt

Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Drug Resistance, Neoplasm
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39393037
DOI: 10.1200/PO.24.00254
PMCID: PMC11485209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.PMID 39393037Read ↗

Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapySemantic proximity Read ↗

Tumour heterogeneity and the evolution of polyclonal drug resistance.Semantic proximity Read ↗

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast CancerSemantic proximity Read ↗

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast CancerSemantic proximity Read ↗

The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.Semantic proximity Read ↗

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity Read ↗

Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.Semantic proximity Read ↗

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.Semantic proximity Read ↗

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case reportSemantic proximity Read ↗

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.Semantic proximity Read ↗

Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.